Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. (symbol: CABA) is a clinical-stage biotechnology company dedicated to the discovery and development of engineered T cell therapies for patients suffering from B cell-mediated autoimmune diseases. Utilizing its proprietary Chimeric AutoAntibody Receptor (CAAR) and Chimeric Antigen Receptor T cells for autoimmunity (CARTA) technologies, Cabaletta aims to provide targeted, effective, and potentially curative treatments.
The company's flagship product candidate, DSG3-CAART, is in Phase I clinical trials for treating mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Other promising candidates include MuSK-CAART for myasthenia gravis and FVIII-CAART for a subset of patients with hemophilia A. Cabaletta is also actively developing DSG3/1-CAART for mucocutaneous pemphigus vulgaris, with several products in various stages of preclinical and discovery phases.
In recent developments, Cabaletta Bio received approval from the U.S. FDA for its Investigational New Drug (IND) application for CABA-201, a fully human CD19-CAR T cell investigational therapy for generalized myasthenia gravis (gMG). This expands their portfolio into neurology, complementing prior clearances for lupus, myositis, and systemic sclerosis. The upcoming Phase 1/2 clinical trial for CABA-201 aims to test its efficacy in treating gMG patients, potentially offering a groundbreaking one-time dose treatment.
Furthermore, Cabaletta has secured multiple Fast Track Designations from the FDA for CABA-201 in conditions like dermatomyositis and systemic sclerosis, facilitating expedited development and review. These designations highlight the critical unmet needs in these patient populations and amplify Cabaletta’s commitment to pioneering advanced therapies.
Based in Philadelphia, PA, Cabaletta Bio continues to advance its innovative pipeline, guided by robust scientific research and strategic collaborations. The company is well-positioned financially, with adequate resources to fund its operations into the first half of 2026. Cabaletta's mission is to harness the power of engineered T cells to unlock transformative therapies, offering patients durable, drug-free remissions and improved quality of life.
Cabaletta Bio (Nasdaq: CABA), a biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will speak at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 1:30 p.m. ET. The conference will take place at NASDAQ in New York City.
A live webcast of the event will be available on the company's website, with replays accessible for 30 days. Cabaletta Bio is advancing its CABA™ platform, which includes the CARTA and CAART strategies aimed at developing innovative therapies for various autoimmune conditions. Key product candidates include CABA-201 for lupus nephritis and DSG3-CAART for mucosal pemphigus vulgaris. The company is headquartered in Philadelphia, PA, and is dedicated to providing potentially curative treatments for patients.
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company, will have its CEO, Steven Nichtberger, M.D., present at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 9:30 a.m. ET. This presentation will be accessible via a live webcast on the company's website, with replays available for 30 days.
The company focuses on developing curative targeted cell therapies for autoimmune diseases, utilizing its CABA™ platform which includes the CARTA and CAART strategies. Key candidates include CABA-201 for lupus nephritis and systemic lupus erythematosus, DSG3-CAART for mucosal pemphigus vulgaris, and MuSK-CAART for MuSK myasthenia gravis. Cabaletta Bio's headquarters are in Philadelphia, PA.
Cabaletta Bio (Nasdaq: CABA) announced the successful clearance of its IND application for CABA-201, a CAR T cell therapy targeting systemic lupus erythematosus (SLE) and lupus nephritis (LN), by the FDA. This milestone was achieved within six months post-licensing, reflecting an efficient clinical trial design informed by prior data. The planned Phase 1/2 trial aims to evaluate the efficacy and safety of CABA-201, with initial results expected by mid-2024. SLE primarily affects young women and poses significant health risks, impacting an estimated 160,000-320,000 patients in the U.S.
Cabaletta Bio (CABA) anticipates Investigational New Drug (IND) clearance for its CABA-201 treatment by mid-2023, with clinical data expected by mid-2024. This fully human CD19-CAR T therapy targets autoimmune diseases and has shown promising preclinical results. The company announced a net revenue of $32.6 million from a public offering in December 2022. R&D expenses rose to $39.3 million for 2022, up from $32.5 million in 2021, while general and administrative costs also increased. Despite these expenses, Cabaletta's cash reserves stood at $106.5 million as of December 31, 2022, ensuring operational funding through Q1 2025.
On February 28, 2023, Cabaletta Bio (Nasdaq: CABA) announced that CEO Steven Nichtberger, M.D., will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference. This event is set for March 7, 2023, at 2:10 p.m. ET in Boston, MA. A live webcast will be accessible on the company’s website, with replays available for 30 days post-event.
Cabaletta Bio focuses on developing innovative T cell therapies aimed at treating autoimmune diseases. Their CABA™ platform includes the CARTA and CAART strategies, with promising candidates like CABA-201 and DSG3-CAART, which may offer curative solutions for various conditions.
Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will present at the 41st Annual J.P. Morgan Conference on January 12th at 7:30 a.m. PT in San Francisco. A live webcast will be available on the company’s website, and replays will be accessible for 30 days. Cabaletta Bio aims to develop potentially curative therapies through its CABA™ platform, which includes lead candidates CABA-201 and DSG3-CAART for conditions like mucosal pemphigus vulgaris.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
What is Cabaletta Bio's primary focus?
What are some of Cabaletta Bio's key product candidates?
What is CABA-201 and why is it significant?
Has Cabaletta Bio received any regulatory designations?
Where is Cabaletta Bio headquartered?
What is the current financial condition of Cabaletta Bio?
What stages are Cabaletta Bio's clinical trials in?
What makes Cabaletta Bio's technology proprietary?
What recent achievements has Cabaletta Bio made?
How does Cabaletta Bio aim to impact patient care?
